Clinical Trial Update: Lucentis for Inflammatory Macular Edema Trial [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial of Lucentis (ranibizumab) for inflammatory macular edema associated with uveitis has completed. Results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystoid Macular Edema
• Uveitis

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Uveitis, Cytoid Macular Edema | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2012-09-21